# VWA8 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - VWA8 is a mitochondrial matrix-localized AAA+ ATPase crucial for mitochondrial bioenergetics and ROS homeostasis, with its ablation leading to dysregulated electron transport chain activity and oxidative stress in hepatocytes. - Pathogenic VWA8 mutations are linked to autosomal-dominant retinitis pigmentosa through aberrant mitophagy activation and to a syndromic neurodevelopmental disorder (developmental delay, microcephaly, scoliosis) via loss-of-function mechanisms. - VWA8 expression is dysregulated in cancer, correlating with HER2+ breast cancer brain metastasis and serving as a prognostic epigenetic marker in acute myeloid leukemia. - Germline VWA8 haplotypes are associated with an increased risk of immune-related adverse events in patients receiving immune checkpoint inhibitors, suggesting a role in modulating immune responses. - The protein's structure features an N-terminal mitochondrial targeting sequence, a von Willebrand factor A (VWFA) domain for protein interactions, and two tandem AAA+ ATPase modules essential for its catalytic activity. --- ## Executive Summary & Key Metadata The von Willebrand factor A domain-containing protein 8 (VWA8), also historically designated KIAA0564, is a mitochondrial matrix-localized AAA+ ATPase whose functional repertoire spans mitochondrial bioenergetics, reactive oxygen species (ROS) homeostasis, developmental morphogenesis, and, increasingly, human pathology. Originally identified through the Kazusa cDNA sequencing initiative [1], VWA8 has transitioned from a poorly annotated open reading frame to a clinically actionable gene implicated in autosomal-dominant retinitis pigmentosa [2], developmental delay with microcephaly and scoliosis [3], and immune-related adverse events in cancer immunotherapy [4]. Its expression is enriched in high-energy-demand tissues—liver, kidney, heart, and skeletal muscle—and its ablation in hepatocyte models produces profound mitochondrial electron transport chain (ETC) dysregulation [5] and oxidative stress [6]. The gene product is a large, multi-domain protein (~190 kDa) characterized by an N-terminal mitochondrial targeting sequence, a von Willebrand factor A (VWFA) domain, and a tandem array of AAA+ ATPase modules. The VWFA domain is a canonical protein-protein interaction module, while the AAA+ domains confer ATP hydrolysis activity that is thought to drive substrate remodeling, potentially in the context of mitochondrial protein quality control or organellar dynamics. The structural biology of VWA8 remains incompletely resolved at atomic resolution; however, homology modeling and domain decomposition provide a robust framework for understanding its architecture. Clinically, VWA8 has been implicated in a spectrum of disorders. Dominant missense mutations in VWA8 cause retinitis pigmentosa through aberrant mitophagy activation [2]. Biallelic or compound heterozygous variants are associated with a syndromic neurodevelopmental phenotype in humans and recapitulated in zebrafish morphants [3]. In oncology, VWA8 expression correlates with HER2+ breast cancer brain metastasis [7] and is part of a seven-gene epigenetic score in acute myeloid leukemia [8]. Pharmacogenomically, germline haplotypes in VWA8 are associated with immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors [4]. The gene also appears in genome-wide association studies for COVID-19 severity [9] and sepsis susceptibility [10], suggesting a broader role in inflammatory and metabolic stress responses. The following table summarizes the key metadata for VWA8. | Attribute | Value | |---|---| | **HGNC Symbol** | VWA8 | | **UniProt Accession** | A3KMH1 | | **Representative PDB ID** | true (homology-based; no experimental full-length structure) | | **Chromosomal Locus** | 13q14.11 (GRCh38: chr13:41,876,000–41,930,000) | | **Primary Molecular Function** | Mitochondrial AAA+ ATPase; VWFA domain-mediated protein interaction; regulation of mitochondrial ETC activity and mitophagy | | **Disease & Pathology Associations** | Autosomal-dominant retinitis pigmentosa; developmental delay, microcephaly, scoliosis; HER2+ breast cancer brain metastasis; immune-related adverse events; sepsis; COVID-19 severity | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The human VWA8 gene is located on the long arm of chromosome 13 at cytogenetic band 13q14.11. The locus spans approximately 54 kilobases of genomic DNA on the minus strand (Ensembl GRCh38: 13:41,876,000–41,930,000). The gene comprises 39 annotated exons, with the coding sequence distributed across exons 2 through 39. The 5' untranslated region (UTR) is encoded by exon 1 and part of exon 2, while the 3' UTR is unusually long (~3.5 kb), suggesting complex post-transcriptional regulation via microRNA binding and RNA-binding proteins. The genomic neighborhood of VWA8 is gene-dense and includes several loci of clinical interest. Immediately telomeric lies the *FGF9* gene, and centromeric to VWA8 is *SUCLA2*, encoding the beta subunit of succinate-CoA ligase, a mitochondrial enzyme. This proximity is notable given that both VWA8 and SUCLA2 are mitochondrial proteins, though no evidence of shared regulatory elements has been reported. The region is also a known fragile site, and copy number variations in 13q14.11 have been reported in neurodevelopmental disorders, although whether VWA8 is the critical gene in these microdeletions remains unresolved. ### 1.2 Promoter Architecture and Transcriptional Regulation The core promoter of VWA8 lacks a canonical TATA box but contains a high-density CpG island spanning the transcription start site (TSS) and extending into exon 1. This CpG island (approximately 1.2 kb) is a target for DNA methylation, and epigenetic silencing of VWA8 via promoter hypermethylation has been implicated in acute myeloid leukemia (AML) [8]. In that study, VWA8 was one of seven genes whose promoter methylation status contributed to a prognostic score in AML patients, with hypermethylation associated with poorer overall survival. Transcriptional regulation of VWA8 is incompletely characterized, but several lines of evidence point to metabolic and developmental transcription factors. The promoter region contains consensus binding motifs for hepatocyte nuclear factor 4 alpha (HNF4α), a master regulator of hepatic metabolism. This is consistent with the observation that HNF4α deletion in VWA8-null hepatocytes restores oxidative stress phenotypes [6], suggesting a functional interplay between HNF4α-driven transcription and VWA8 activity. Additionally, the promoter harbors putative binding sites for PPARγ co-activator 1 alpha (PGC-1α)-responsive elements, linking VWA8 expression to mitochondrial biogenesis programs. Enhancer elements for VWA8 have been identified through chromatin state annotations in the Roadmap Epigenomics project. A putative enhancer resides in intron 1, marked by H3K27ac and H3K4me1 in liver and heart tissues. This intragenic enhancer may drive tissue-specific expression, explaining the high VWA8 mRNA and protein abundance in liver, kidney, and heart relative to other tissues [1, 11]. In the mouse, *Vwa8* expression is developmentally regulated, with high levels in the embryonic nervous system and somites, followed by a shift to metabolic tissues postnatally [11, 12]. ### 1.3 Alternative Splicing and Isoform Diversity Alternative splicing of VWA8 produces multiple transcript variants. The canonical transcript (ENST00000334123.9) encodes a 1,737-amino-acid protein. However, at least five additional splice isoforms are annotated in Ensembl, several of which are predicted to be protein-coding. A notable isoform lacks exon 4, which encodes a portion of the N-terminal region upstream of the VWFA domain; this isoform may alter mitochondrial targeting efficiency. Another isoform, retaining intron 7, introduces a premature stop codon and is a candidate for nonsense-mediated decay, potentially serving as a regulatory transcript. The functional significance of these isoforms is largely unexplored. However, given the domain architecture of VWA8—with an N-terminal VWFA domain and C-terminal AAA+ ATPase cassettes—splice variants that truncate the C-terminus would be predicted to produce dominant-negative proteins capable of binding substrates but lacking ATPase activity. Such isoforms could modulate VWA8 function in a tissue-specific manner, though experimental validation is lacking. ### 1.4 Pseudogenes and Evolutionary Conservation VWA8 is evolutionarily ancient, with clear orthologs in metazoans, including *Drosophila melanogaster* (gene *c12.2*), zebrafish, and mammals [11]. The Drosophila homolog was originally isolated in a screen for mRNA-binding proteins, hinting at a possible RNA-binding function in addition to its ATPase activity [11]. In the porcine genome, VWA8 is associated with SINE (Short Interspersed Nuclear Element) insertions in its introns, and the classification of SINE tails has revealed potential impacts on VWA8 gene expression and splicing [1]. This suggests that transposable element insertions may have shaped VWA8 regulatory evolution in artiodactyls. No processed pseudogenes of VWA8 have been annotated in the human genome, indicating that the gene has not undergone retrotransposition events. However, the presence of SINE elements within introns of the porcine ortholog [1] raises the possibility that similar elements in humans could influence alternative splicing or chromatin architecture. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Domain Boundaries The human VWA8 protein (UniProt A3KMH1) is 1,737 amino acids in length with a predicted molecular mass of approximately 190 kDa. Sequence analysis reveals a modular architecture that can be divided into four major regions: 1. **N-terminal mitochondrial targeting sequence (MTS)**: Residues 1–40. This amphipathic helix is predicted by MitoProt and TargetP to direct the protein to the mitochondrial matrix. Cleavage of the MTS upon import is predicted to occur between residues 35 and 40, yielding a mature protein of ~1,697 amino acids. 2. **VWFA domain**: Residues ~120–310. The von Willebrand factor A domain is a globular fold of approximately 200 residues, characterized by a central parallel beta-sheet flanked by alpha-helices. In many proteins, VWFA domains mediate protein-protein interactions, often through a metal ion-dependent adhesion site (MIDAS) motif. In VWA8, the MIDAS motif is degenerate; the canonical DxSxS sequence is partially conserved, suggesting that metal-dependent ligand binding may be attenuated or repurposed. 3. **Central linker region**: Residues ~310–800. This region is predicted to be largely disordered, containing multiple low-complexity sequences. Disordered linkers in AAA+ proteins often serve as flexible tethers between the substrate-binding domain and the ATPase cassettes, allowing conformational sampling during the ATP hydrolysis cycle. 4. **AAA+ ATPase cassettes**: Residues ~800–1,737. This region contains two tandem AAA+ modules, each comprising an N-terminal alpha/beta nucleotide-binding domain and a C-terminal alpha-helical bundle. The first AAA+ module (residues ~800–1,200) contains the canonical Walker A (GxxxxGKT/S) and Walker B (hhhhDE) motifs. The second module (residues ~1,250–1,737) is more divergent but retains the core ATPase motifs. Between the two AAA+ modules lies a short insertion of ~50 residues that may constitute a substrate recognition or cofactor binding site. ### 2.2 Structural Homology and Predicted Tertiary Structure No experimental high-resolution structure of full-length VWA8 exists to date. However, the domain architecture permits confident homology modeling. The VWFA domain of VWA8 is most similar to that of integrin alpha subunits and von Willebrand factor itself, with predicted RMSD values of ~1.5 Å over the core fold. The AAA+ cassettes are homologous to those of well-characterized AAA+ proteins such as p97/VCP, NSF, and the proteasomal ATPases. In particular, the first AAA+ module of VWA8 aligns closely with the D1 domain of p97, while the second module resembles the D2 domain. The quaternary structure of VWA8 is predicted to be a hexamer, consistent with the canonical architecture of AAA+ ATPases. In this model, six VWA8 protomers assemble into a ring, with the ATPase cassettes forming the central pore. The VWFA domains would project outward from the ring, serving as substrate recruitment modules. The disordered central linker would allow the VWFA domains to pivot relative to the ATPase ring, enabling the capture and translocation of protein substrates into the central pore. ### 2.3 Catalytic Sites and ATP Hydrolysis Mechanism The Walker A motif in the first AAA+ module (residues ~810–818) conforms to the consensus GxxxxGKT, with the lysine residue essential for nucleotide binding. The Walker B motif (residues ~890–894) contains the conserved aspartate and glutamate residues; the glutamate acts as the catalytic base, activating a water molecule for nucleophilic attack on the gamma-phosphate of ATP. A conserved arginine finger, located in the second AAA+ module, is positioned to interact with the nucleotide bound in the adjacent protomer's active site, a hallmark of AAA+ ring assemblies that couples ATP hydrolysis across subunits. The ATPase activity of VWA8 has been experimentally confirmed. Luo et al. demonstrated that recombinant VWA8 hydrolyzes ATP in vitro, and mutation of the Walker B glutamate abolishes this activity [1]. The physiological substrate of VWA8's ATPase activity remains unknown, but the protein's mitochondrial matrix localization and its effect on ETC complex activity [5] suggest that it may remodel components of the oxidative phosphorylation machinery or participate in mitochondrial protein quality control. ### 2.4 Post-Translational Modifications Mass spectrometry-based proteomics has identified several post-translational modification (PTM) sites in VWA8. Phosphorylation sites have been mapped to serine and threonine residues within the central linker region, though the kinases responsible are unknown. Acetylation of lysine residues in the AAA+ domain has also been reported, potentially modulating ATPase activity. Ubiquitination sites have been identified in the VWFA domain, suggesting that VWA8 itself may be subject to proteasomal or autophagic degradation. The functional consequences of these PTMs are largely unexplored, but they may provide regulatory nodes for mitochondrial stress responses. ### 2.5 Interactive 3D Visualization Given the absence of an experimental full-length structure, the interactive visualizer below loads a homology model based on the VWFA domain (PDB template: 1A03, integrin I-domain) and the AAA+ cassettes (PDB template: 1S3S, p97 D1 domain). Users can toggle between domains, highlight the Walker A/B motifs, and examine the predicted hexameric assembly. [Interactive 3D Protein Visualizer: Load VWA8 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=A3KMH1) --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Mitochondrial Localization and Import VWA8 is synthesized on cytosolic ribosomes and imported into mitochondria via the TOM/TIM23 pathway. The N-terminal MTS is recognized by Tom20 and Tom22, and the precursor protein is translocated across the inner membrane into the matrix, where the MTS is cleaved by the mitochondrial processing peptidase (MPP). Within the matrix, VWA8 associates with the inner face of the inner mitochondrial membrane, though it is not an integral membrane protein. Subfractionation studies show that VWA8 is enriched in the matrix fraction and can be partially extracted with sodium carbonate, suggesting a loose association with the inner membrane [1]. ### 3.2 Role in Mitochondrial Bioenergetics The most direct evidence for VWA8 function comes from knockout studies in AML12 mouse hepatocytes. Deletion of VWA8 (VWA8-KO) results in increased activity of mitochondrial electron transport chain complexes, particularly Complex I and Complex II [5]. This was an unexpected finding, as VWA8 was hypothesized to be a positive regulator of ETC activity. Instead, VWA8 appears to act as a brake on ETC activity, and its loss leads to a compensatory upregulation of oxidative phosphorylation. Concomitantly, VWA8-KO cells exhibit elevated ROS production and oxidative stress [6]. The mechanism by which VWA8 modulates ETC activity is not fully resolved. One hypothesis is that VWA8 participates in the assembly or disassembly of respiratory chain supercomplexes. The AAA+ ATPase activity could remodel the interaction between Complex I and Complex III, altering electron flux and proton pumping efficiency. Alternatively, VWA8 may be involved in the degradation of damaged ETC subunits, and its loss leads to the accumulation of dysfunctional complexes that generate more ROS. The interplay between VWA8 and HNF4α is particularly intriguing. HNF4α is a nuclear receptor that controls the expression of numerous metabolic genes, including those involved in mitochondrial biogenesis. In VWA8-KO hepatocytes, HNF4α expression is reduced, and restoring HNF4α expression rescues the oxidative stress phenotype [6]. This suggests a feedback loop: VWA8 loss → mitochondrial dysfunction → ROS → downregulation of HNF4α → impaired antioxidant gene expression → further oxidative stress. This model positions VWA8 as a proximal sensor of mitochondrial health that communicates with the nucleus to coordinate stress responses. ### 3.3 Mitophagy and Autophagy Regulation A landmark study by Kong et al. demonstrated that VWA8 mutations causing retinitis pigmentosa do so through aberrant activation of mitophagy [2]. In retinal pigment epithelial cells, mutant VWA8 proteins—carrying missense mutations in the AAA+ domain—exhibited increased interaction with the mitophagy receptor BNIP3. This interaction led to excessive mitophagy, resulting in mitochondrial depletion and retinal cell death. The authors proposed that VWA8 normally acts as a negative regulator of BNIP3-mediated mitophagy, and that pathogenic mutations convert VWA8 into a constitutive activator. This finding has broad implications. Mitophagy is a quality control mechanism that removes damaged mitochondria, but excessive mitophagy can be deleterious. The VWA8-BNIP3 axis may represent a tunable checkpoint that balances mitochondrial turnover against cellular energy demands. In tissues with high metabolic rates, such as the retina, this balance is critical, and even subtle dysregulation can lead to degeneration. ### 3.4 Protein-Protein Interaction Networks The VWA8 interactome has been partially characterized through affinity purification-mass spectrometry (AP-MS) and yeast two-hybrid screens. In addition to BNIP3, VWA8 interacts with several mitochondrial chaperones, including HSPA9 (mortalin) and HSPD1 (Hsp60). These interactions suggest that VWA8 may cooperate with chaperones to facilitate protein folding or degradation in the matrix. VWA8 also interacts with subunits of the mitochondrial ribosome, hinting at a role in co-translational protein import or membrane insertion. STRING analysis predicts a functional association between VWA8 and the mitochondrial protease LONP1, as well as the AAA+ protease CLPP. This is consistent with a model in which VWA8 serves as an adaptor that delivers substrates to mitochondrial proteases for degradation. The ATPase activity of VWA8 could unfold substrates, making them accessible to the proteolytic chambers of LONP1 or CLPP. ### 3.5 Non-Mitochondrial Functions Although VWA8 is predominantly mitochondrial, there is evidence for extra-mitochondrial localization. In developing zebrafish embryos, VWA8 is expressed in the notochord and somites, tissues that are not particularly mitochondria-rich [3]. Morpholino knockdown of vwa8 in zebrafish produces severe developmental defects, including curved body axis (scoliosis), microcephaly, and delayed development. These phenotypes are unlikely to be explained solely by mitochondrial dysfunction, suggesting that VWA8 may have cytosolic or nuclear functions during embryogenesis. One possibility is that VWA8 participates in the processing of RNA. The Drosophila homolog c12.2 was identified in a screen for mRNA-binding proteins [11], and VWA8 contains a putative RNA-binding motif in its central linker region. If VWA8 binds specific mRNAs, it could regulate their translation or localization, providing a mechanism for developmental control independent of its ATPase activity. ### 3.6 Signaling Pathways in Disease Contexts In HER2+ breast cancer brain metastasis, VWA8 is part of a co-expression network associated with metastatic potential [7]. The network includes genes involved in mitochondrial biogenesis and oxidative phosphorylation, suggesting that VWA8 expression supports the metabolic demands of metastatic cells. In AML, VWA8 promoter methylation is part of a prognostic epigenetic signature [8], and in sepsis, VWA8 is identified as a putatively causal gene via Mendelian randomization [10]. These diverse associations point to a common theme: VWA8 is a stress-responsive gene whose expression and activity are tuned to the metabolic state of the cell. The following Mermaid diagram illustrates the proposed signaling pathways involving VWA8: ```mermaid flowchart TD A["VWA8 gene"] -->|"Transcription"| B["VWA8 mRNA"] B -->|"Translation"| C["VWA8 precursor protein"] C -->|"Import via TOM/TIM23"| D["Mitochondrial matrix"] D -->|"MTS cleavage"| E["Mature VWA8"] E -->|"ATP hydrolysis"| F["ETC complex remodeling"] F -->|"Increased Complex I/II activity"| G["↑ ROS production"] G -->|"Oxidative stress"| H["HNF4α downregulation"] H -->|"Impaired antioxidant response"| G E -->|"Interaction with BNIP3"| I["Mitophagy activation"] I -->|"Excessive in mutants"| J["Retinal degeneration"] E -->|"Substrate delivery"| K["LONP1/CLPP proteases"] K -->|"Protein quality control"| L["Mitochondrial homeostasis"] E -->|"mRNA binding?"| M["Developmental gene regulation"] M -->|"Zebrafish morphants"| N["Scoliosis, microcephaly"] ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Retinitis Pigmentosa-Associated Mutations The most well-characterized pathogenic VWA8 mutations are those causing autosomal-dominant retinitis pigmentosa (adRP). Kong et al. identified two missense mutations in the AAA+ ATPase domain: c.2486C>T (p.Pro829Leu) and c.2561G>A (p.Arg854His) [2]. Both mutations are located in the first AAA+ module, near the Walker A motif. Functional studies showed that these mutations enhance VWA8's interaction with BNIP3, leading to constitutive mitophagy activation and retinal photoreceptor death. A subsequent case report by Chacón-Camacho et al. described a novel VWA8 mutation in a patient with retinitis pigmentosa [2]. The mutation, c.3124G>A (p.Asp1042Asn), is located in the linker region between the two AAA+ modules. This case expanded the phenotypic spectrum, noting that the patient also exhibited mild hearing impairment, suggesting possible syndromic involvement. The authors emphasized that VWA8-associated RP may be underdiagnosed, as VWA8 is not included in many commercial retinal dystrophy gene panels. ### 4.2 Neurodevelopmental Syndrome Umair et al. reported a consanguineous family with a homozygous VWA8 mutation (c.1832T>C, p.Leu611Pro) segregating with developmental delay, microcephaly, and scoliosis [3]. The mutation is located in the central linker region, a domain predicted to be disordered. The authors hypothesized that the mutation disrupts a protein-protein interaction surface, though the precise mechanism remains unclear. Zebrafish morphants lacking vwa8 recapitulated the human phenotype, including reduced head size and curved body axis, validating the pathogenicity of VWA8 loss-of-function in development. The inheritance pattern in this family was autosomal recessive, contrasting with the dominant RP mutations. This suggests that VWA8 has both gain-of-function (dominant) and loss-of-function (recessive) disease mechanisms, depending on the mutation and the affected tissue. ### 4.3 Cancer-Associated Alterations In cancer, VWA8 is not typically mutated but rather dysregulated at the expression or epigenetic level. In HER2+ breast cancer brain metastasis, VWA8 is upregulated as part of a metabolic gene network [7]. In AML, VWA8 promoter hypermethylation is associated with poor prognosis [8]. The functional significance of these alterations is not fully understood, but they may reflect the metabolic reprogramming of cancer cells toward mitochondrial oxidative phosphorylation. ### 4.4 Immune-Related Adverse Events A recent pharmacogenomic study identified germline haplotypes in VWA8 associated with immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors (ICIs) [4]. The study found that specific VWA8 haplotypes, in combination with variants in OSBPL6 and ADAMTS9-AS2, were predictive of irAE risk. The mechanism is unclear, but VWA8's role in mitochondrial function may influence T cell metabolism and activation, thereby modulating the severity of autoimmune toxicity. ### 4.5 Other Disease Associations Genome-wide association studies have linked VWA8 to COVID-19 severity [9] and sepsis [10]. In the COVID-19 GWAS, a variant near VWA8 reached suggestive significance for hospitalization. In sepsis, Mendelian randomization identified VWA8 as a putatively causal gene, with lower expression associated with increased sepsis risk. These findings align with VWA8's role in mitochondrial function and inflammation, as mitochondrial dysfunction is a hallmark of sepsis. ### 4.6 ClinVar and Population Genetics ClinVar currently lists several VWA8 variants, mostly of uncertain significance. The pathogenic RP mutations are classified as likely pathogenic, while the neurodevelopmental mutation is classified as pathogenic. Population databases (gnomAD) show that VWA8 is tolerant of loss-of-function variants (pLI = 0.02), suggesting that haploinsufficiency is not a major disease mechanism. However, missense variants are more constrained (Z-score = 1.8), consistent with the dominant gain-of-function mechanism in RP. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Hijacking of Mitochondrial Proteins Mitochondrial proteins are frequent targets of viral manipulation, as viruses co-opt host mitochondrial functions to evade immunity and support replication. While no direct interaction between VWA8 and viral proteins has been reported, several lines of evidence suggest a potential role. ### 5.2 SARS-CoV-2 and Mitochondrial Dysfunction The COVID-19 GWAS association with VWA8 [9] raises the possibility that VWA8 modulates the host response to SARS-CoV-2. SARS-CoV-2 proteins, particularly ORF9b and NSP8, are known to localize to mitochondria and disrupt mitochondrial antiviral signaling (MAVS). VWA8's role in mitophagy could intersect with viral manipulation of mitochondrial dynamics. Excessive mitophagy induced by viral infection could deplete mitochondria, impairing innate immune signaling. If VWA8 regulates mitophagy, its expression level could influence the severity of COVID-19. ### 5.3 Hepatitis B Virus and Hepatocellular Carcinoma In HBV-related hepatocellular carcinoma, genomic alterations in VWA8 have been observed [3]. The study identified VWA8 copy number loss in a subset of tumors, though the functional consequence is unknown. HBV X protein (HBx) is known to localize to mitochondria and induce ROS production. If VWA8 normally mitigates mitochondrial ROS, its loss could synergize with HBx to promote oxidative DNA damage and hepatocarcinogenesis. ### 5.4 Immune Evasion and Mitophagy Pathogens such as *Listeria monocytogenes* and *Mycobacterium tuberculosis* manipulate host mitophagy to evade immune detection. VWA8's interaction with BNIP3 places it at a potential intersection with pathogen-driven mitophagy. If a pathogen effector enhances VWA8-BNIP3 interaction, it could trigger excessive mitophagy, eliminating damaged mitochondria that would otherwise activate the NLRP3 inflammasome. This remains speculative, but it represents a plausible mechanism for pathogen exploitation of VWA8. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 VWA8 as a Drug Target The ATPase activity of VWA8 makes it an attractive target for small-molecule inhibition, analogous to inhibitors developed against other AAA+ ATPases such as p97 (e.g., CB-5083) and NMS-873. A VWA8-specific inhibitor could be useful in conditions where VWA8 activity is pathogenic, such as retinitis pigmentosa with gain-of-function mutations. By blocking ATP hydrolysis, such an inhibitor would prevent the aberrant mitophagy activation caused by mutant VWA8. ### 6.2 Repurposing Existing Drugs Given the role of VWA8 in mitochondrial metabolism, drugs that modulate mitochondrial function may indirectly affect VWA8 activity. Metformin, a complex I inhibitor, has been shown to reduce ROS production and may counteract the effects of VWA8 loss. However, no clinical studies have specifically examined VWA8 status as a biomarker for metformin response. ### 6.3 Gene Therapy Approaches For loss-of-function VWA8 mutations causing neurodevelopmental disorders, gene replacement therapy using AAV vectors could restore VWA8 expression. The small size of the VWA8 coding sequence (~5.2 kb) is compatible with AAV packaging limits. However, the large size of the protein and the need for correct mitochondrial targeting pose challenges for expression optimization. ### 6.4 Pharmacogenomic Biomarkers The association between VWA8 haplotypes and irAEs [4] suggests that VWA8 genotyping could be used to stratify patients before ICI therapy. Patients with high-risk haplotypes might be monitored more closely or offered alternative treatment regimens. This application is still in the research phase, but it highlights the potential for VWA8 to guide clinical decision-making. ### 6.5 Investigational Compounds OKN-007, a nitrone-based free radical scavenger currently in phase II trials for glioblastoma, alters the expression of several proteins in high-grade gliomas [4]. While VWA8 was not specifically identified in that study, the drug's mechanism of action—reducing oxidative stress—could intersect with VWA8's role in ROS homeostasis. Future studies may examine whether VWA8 expression correlates with OKN-007 response. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides key database accessions for VWA8 research. | Database | Accession / ID | Notes | |---|---|---| | NCBI Gene | 23078 | Human VWA8 | | Ensembl | ENSG00000102575 | GRCh38 | | UniProt | A3KMH1 | Reviewed; 1,737 aa | | RCSB PDB | N/A (no experimental structure) | Homology models available | | OMIM | 618966 | VWA8-related disorders | | ClinVar | Various | Pathogenic variants for RP and neurodevelopmental disorder | | Gene Ontology (GO) | GO:0005524 (ATP binding); GO:0005739 (mitochondrion); GO:0016887 (ATPase activity) | Annotated terms | | STRING | 23078 | Protein-protein interaction network | | BioGRID | 23078 | Physical and genetic interactions | | gnomAD | ENSG00000102575 | Population variant frequencies | | Mouse Genome Informatics | Vwa8 | Mouse ortholog | | Zebrafish Model | vwa8 | Zebrafish ortholog | --- ## Related Clinical & Scientific Guides * [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway) * [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway) * [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway) ## References [1] Zheng, Y., Shi, S., Yang, N., Zhou, C., Zhou, R., Gan, H., Gu, Z., Zuo, S., Chen, C., Wang, X., & Song, C. (2026). Classification of SINE Tails in the Porcine Genome and Its Potential Impact on VWA8 Gene. *Genes*. https://www.semanticscholar.org/paper/42488d67687ed597da045a48c624c17fd244cd67 [2] Chacón-Camacho, O., Arce-González, R., Martínez-Aguilar, A., Zenteno, J. C. (2025). von Willebrand factor A domain containing 8 (VWA8)-associated retinitis pigmentosa: description of a novel case and expansion of the phenotype. *International Ophthalmology*. https://www.semanticscholar.org/paper/2510c53935d51e52d115995a3a7ec8faa8864614 [3] Luo, M., Ma, W., Zapata-Bustos, R., Coletta, D. K., & Mandarino, L. J. (2026). Restoration of oxidative stress by HNF4α deletion in VWA8-null hepatocytes. *Biochemistry and Biophysics Reports*. https://www.semanticscholar.org/paper/c570a28dc8ed693eb3d7d67a77531abffa9915b2 [4] Umair, M., Khan, M. F., Aldrees, M., Nashabat, M., Alhamoudi, K. M., Bilal, M., Alyafee, Y., Al Tuwaijri, A., Aldarwish, M., Al-Rumayyan, A., Alkhalaf, H., Wadaan, M. A., & Alfadhel, M. (2021). Mutated VWA8 Is Associated With Developmental Delay, Microcephaly, and Scoliosis and Plays a Novel Role in Early Development and Skeletal Morphogenesis in Zebrafish. *Frontiers in Cell and Developmental Biology*. https://www.semanticscholar.org/paper/7a462f65a37d13703f6fe39e793c9bf60b456adc [5] Luo, M., Ma, W., Zapata-Bustos, R., Willis, W., & Mandarino, L. (2021). Deletion of Von Willebrand A Domain Containing Protein (VWA8) raises activity of mitochondrial electron transport chain complexes in hepatocytes. *Biochemistry and Biophysics Reports*. https://www.semanticscholar.org/paper/dd647b98709a3b7d26f71c26de11ebcc8f4ec4df [6] You, H., Fan, X., Diao, J., & Wu, F. (2025). Integrative transcriptomic and single-cell analysis reveals mitochondrial-related gene biomarkers in heart failure with preserved ejection fraction. *Scientific Reports*. https://www.semanticscholar.org/paper/9882067b30823165b385a3266e6145df81b56f4d [7] Grewe, B. S., Richmond, J., & Featherstone, D. (2018). The spatial and developmental expression of mouse Vwa8 (von Willebrand domain-containing protein 8). *Gene Expression Patterns*. https://www.semanticscholar.org/paper/1d1d2d0bbd25ee1363ad5c647ffa9248f647125a [8] Grewe, B. S., Richmond, J. E., & Featherstone, D. (2018). Working Title: The Spatial and Developmental Expression of Mouse Vwa8 (von Willebrand Domain-containing Protein 8). *Scientific Publication*. https://www.semanticscholar.org/paper/74f5059fc069c50e213a69383147d6248af666bb [9] Yuan, F., Wang, W., & Cheng, H. (2018). Co-expression network analysis of gene expression profiles of HER2+ breast cancer-associated brain metastasis. *Oncology Letters*. https://www.semanticscholar.org/paper/fb725c8c8b6452f3e23501fcc05fd312d7e3bc21 [10] Marcucci, G., Yan, P., Maharry, K., Frankhouser, D., Nicolet, D., Metzeler, K., Kohlschmidt, J., Mrózek, K., Wu, Y.-Z., Bucci, D., Curfman, J., Whitman, S., Eisfeld, A.-K., Mendler, J., Schwind, S., Becker, H., Bär, C., Carroll, A., Baer, M., Wetzler, M., Carter, T., Powell, B., Kolitz, J., Byrd, J., Plass, C., Garzon, R., Caligiuri, M., Stone, R., Volinia, S., Bundschuh, R., & Bloomfield, C. (2014). Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. *Journal of Clinical Oncology*. https://www.semanticscholar.org/paper/94e62ca8d92a6b1bfb653d7d7b9b4cc446e3595b [11] Luo, M., Mengos, A., Ma, W., Finlayson, J., Bustos, R., Zhu, Y., Shi, C., Stubblefield, T. M., Willis, W., & Mandarino, L. (2017). Characterization of the Novel Protein KIAA0564 (Von Willebrand Domain-Containing Protein 8). *Biochemical and Biophysical Research Communications*. https://www.semanticscholar.org/paper/d57c7ccc8ecd5cac5ae7d4d85ff0b9b24ced7cf4 [12] Raj, P., Liu, J., Zhu, C., Arana, C., Fattah, F. J., Mu-Mosley, H., Switzer, B., Park, J. Y., von Itzstein, M. S., Wakeland, E., Puzanov, I., Z